Showing results (1-10 of 162) with videos related to
Sort By:
Pageof 17
Annals of Neurology|February 21, 2013
On being a neurologist in industryDavid Leppert, Robert GlanzmanLancet (London, England)|November 4, 2011
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trialLudwig Kappos, David Li, Peter A Calabresi, et al.Muscle & Nerve|April 6, 2007
Matrix metalloproteinases in neuromuscular diseaseSusanne Renaud, David LeppertJournal of the Neurological Sciences|August 4, 2007
The role of optical coherence tomography in multiple sclerosis: expert panel consensusRobert C Sergott, Elliot Frohman, Robert Glanzman, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 3, 2012
EDSS variability before randomization may limit treatment discovery in primary progressive MSJiameng Zhang, Emmanuelle Waubant, Gary Cutter, et al.Neurology|December 10, 2003
Stimulus recognition and its relationship to the cerebral event-related potentialDavid Leppert, Douglas S Goodin, Michael J AminoffCellular and Molecular Life Sciences : CMLS|June 8, 2019
MMPs and ADAMs in neurological infectious diseases and multiple sclerosisLukas Muri, David Leppert, Denis Grandgirard, et al.Analytical Biochemistry|April 29, 2004
Characterization of Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, a fluorogenic substrate with increased specificity constants for collagenases and tumor necrosis factor converting enzymeUlf Neumann, Hisashi Kubota, Karl Frei, et al.Infection and Immunity|February 5, 2014
Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitisFabian D Liechti, Denis Grandgirard, David Leppert, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 19, 2017
Fluid biomarker and electrophysiological outcome measures for progressive MS trialsChristian Barro, Letizia Leocani, David Leppert, et al.Pageof 17